Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Melanoma 10Carcinoma, Non-Small-Cell Lung 9Carcinoma, Renal Cell 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Pemetrexed 9Cisplatin 9pembrolizumab 5defactinib 3Cyclophosphamide 3sodium thiosulfate 2Radiotherapy, Intensity-Modulated 2Platinum 2Immunoenzyme Techniques 2Doxorubicin 21,2-diaminocyclohexaneplatinum II citrate 2vatalanib 1spartalizumab 1osimertinib 1nintedanib 1liposomal doxorubicin 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1amatuximab 1alvocidib 1aldesleukin 1X-Rays 1VS-5584 1Trabectedin 1Tetrahydrouridine 1Specimen Handling 1Ramucirumab 1Radiotherapy 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Mesothelioma, Malignant × spartalizumab × Clear all
NCT03393858 2024-02-07

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Capital Medical University

Phase 1/2 Terminated
10 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡